Opsumit (Macitentan) Patent Expiration, LOE Window & CMS Spending
Opsumit (Macitentan) by Johnson & Johnson: FDA Orange Book core substance LOE 2026-06-05 (last listed 2029-10-18), 12 AB generics, $1.45B 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Johnson & Johnson |
| FDA Application & Pathway | N204410 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2026-06-05 |
| Last Listed Patent or Exclusivity Date | 2029-10-18 |
| Orange Book Patents (*PED Extensions) | 10 patents (5 *PED) |
| Active AB-Rated Generic Competitors | 12 |
| 2024 CMS Total Public Spend | $1.45B |
| 2024 Medicare Part D Spend | $1.23B |
| 2024 Medicaid Spend | $221.2M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 19.8% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.